Legend Biotechcorp Stock Performance
| LEGN Stock | USD 45.17 2.28 4.81% |
The company secures a Beta (Market Risk) of 0.84, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Legend BiotechCorp's returns are expected to increase less than the market. However, during the bear market, the loss of holding Legend BiotechCorp is expected to be smaller as well. Legend BiotechCorp has an expected return of -0.37%. Please make sure to verify Legend BiotechCorp skewness, and the relationship between the total risk alpha and rate of daily change , to decide if Legend BiotechCorp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Legend BiotechCorp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in May 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (3.90) | Five Day Return (3.23) | Year To Date Return (22.84) | Ten Year Return 23.24 | All Time Return 23.24 |
1 | Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights - The Globe and Mail | 02/29/2024 |
2 | CARVYKTI Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with RelapsedRefractory Multiple Myeloma | 03/15/2024 |
3 | FDA Adcomm Favors Expanded Use Of Johnson Johnson, Bristol Myers CAR-T Therapies For Type Of Blood Cancer | 03/18/2024 |
4 | Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report | 03/19/2024 |
5 | GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy | 03/20/2024 |
6 | HC Wainwright Reiterates Buy Rating for Legend Biotech - Defense World | 04/02/2024 |
7 | Johnson Johnsons Carvykti Stands Ahead Of Bristol Myers Rival Blood Cancer Therapy With FDA Approval For Wider Population | 04/08/2024 |
8 | Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results | 04/11/2024 |
9 | FDA Mandates Boxed Warning For Bristol Myers, Johnson Johnson CAR-T-Based Blood Cancer Therapies | 04/19/2024 |
10 | CARVYKTI Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma | 04/22/2024 |
| Begin Period Cash Flow | 787.3 M |
Legend |
Legend BiotechCorp Relative Risk vs. Return Landscape
If you would invest 5,813 in Legend BiotechCorp on January 25, 2024 and sell it today you would lose (1,296) from holding Legend BiotechCorp or give up 22.29% of portfolio value over 90 days. Legend BiotechCorp is currently does not generate positive expected returns and assumes 2.5154% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Legend, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Legend BiotechCorp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Legend BiotechCorp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Legend BiotechCorp, and traders can use it to determine the average amount a Legend BiotechCorp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1466
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LEGN |
Estimated Market Risk
| 2.52 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Legend BiotechCorp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Legend BiotechCorp by adding Legend BiotechCorp to a well-diversified portfolio.
Legend BiotechCorp Fundamentals Growth
Legend Stock prices reflect investors' perceptions of the future prospects and financial health of Legend BiotechCorp, and Legend BiotechCorp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Legend Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.82) % | ||||
| Operating Margin | (1.52) % | ||||
| Current Valuation | 16.28 B | ||||
| Shares Outstanding | 181.91 M | ||||
| Price To Book | 7.69 X | ||||
| Price To Sales | 33.76 X | ||||
| Revenue | 285.14 M | ||||
| Gross Profit | (284.01 M) | ||||
| EBITDA | (421.76 M) | ||||
| Net Income | (518.25 M) | ||||
| Cash And Equivalents | 791.26 M | ||||
| Cash Per Share | 5.11 X | ||||
| Total Debt | 328.67 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 3.83 X | ||||
| Book Value Per Share | 6.88 X | ||||
| Cash Flow From Operations | (384.47 M) | ||||
| Earnings Per Share | (2.94) X | ||||
| Market Capitalization | 8.63 B | ||||
| Total Asset | 1.85 B | ||||
| Retained Earnings | (1.48 B) | ||||
| Working Capital | 1.28 B | ||||
About Legend BiotechCorp Performance
To evaluate Legend BiotechCorp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Legend BiotechCorp generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Legend Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Legend BiotechCorp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Legend's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 43.08 | 45.23 | |
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.41) | (0.43) |
Things to note about Legend BiotechCorp performance evaluation
Checking the ongoing alerts about Legend BiotechCorp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Legend BiotechCorp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Legend BiotechCorp generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 285.14 M. Net Loss for the year was (518.25 M) with loss before overhead, payroll, taxes, and interest of (284.01 M). | |
| Legend BiotechCorp currently holds about 791.26 M in cash with (384.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11. | |
| Latest headline from businesswire.com: CARVYKTI Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma |
- Analyzing Legend BiotechCorp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Legend BiotechCorp's stock is overvalued or undervalued compared to its peers.
- Examining Legend BiotechCorp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Legend BiotechCorp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Legend BiotechCorp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Legend BiotechCorp's stock. These opinions can provide insight into Legend BiotechCorp's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.Note that the Legend BiotechCorp information on this page should be used as a complementary analysis to other Legend BiotechCorp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Legend Stock analysis
When running Legend BiotechCorp's price analysis, check to measure Legend BiotechCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Legend BiotechCorp is operating at the current time. Most of Legend BiotechCorp's value examination focuses on studying past and present price action to predict the probability of Legend BiotechCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Legend BiotechCorp's price. Additionally, you may evaluate how the addition of Legend BiotechCorp to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stocks Directory Find actively traded stocks across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Legend BiotechCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend BiotechCorp. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend BiotechCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Revenue Per Share 1.619 | Quarterly Revenue Growth 1.876 | Return On Assets (0.17) | Return On Equity (0.52) |
The market value of Legend BiotechCorp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend BiotechCorp's value that differs from its market value or its book value, called intrinsic value, which is Legend BiotechCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend BiotechCorp's market value can be influenced by many factors that don't directly affect Legend BiotechCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend BiotechCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend BiotechCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend BiotechCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.